|A tale of three PKCs: epsilon emerges as a driver of pre-neoplastic phenotypes.|
|Jump to Full Text|
|PMID: 21270526 Owner: NLM Status: MEDLINE|
|Karen E Knudsen|
Related Documents :
|3392996 - Use of ricin a-chain to selectively deplete kupffer cells.
1800126 - Thrombin signalling in u937 human monocytic cells is coupled to inositol phosphate form...
20498856 - Clostridial glucosylating toxins enter cells via clathrin-mediated endocytosis.
2994746 - Modification of the carbohydrate in ricin with metaperiodate and cyanoborohydride mixtu...
14759646 - The role of trans-membrane signal transduction in turing-type cellular pattern formation.
16028066 - Immunolocalization of sex hormone-binding globulin (shbg) in human ovarian follicles an...
|Type: Comment; News Date: 2011-02-01|
|Title: Cell cycle (Georgetown, Tex.) Volume: 10 ISSN: 1551-4005 ISO Abbreviation: Cell Cycle Publication Date: 2011 Feb|
|Created Date: 2011-02-08 Completed Date: 2011-07-04 Revised Date: 2013-06-30|
Medline Journal Info:
|Nlm Unique ID: 101137841 Medline TA: Cell Cycle Country: United States|
|Languages: eng Pagination: 379 Citation Subset: IM|
|APA/MLA Format Download EndNote Download BibTex|
Precancerous Conditions / enzymology*, pathology
Prostate / enzymology, pathology
Prostatic Neoplasms / enzymology*, pathology
Protein Kinase C-alpha / genetics, metabolism
Protein Kinase C-delta / genetics, metabolism
Protein Kinase C-epsilon / genetics*, metabolism
Proto-Oncogene Proteins c-akt / metabolism
STAT3 Transcription Factor / metabolism
|R01 CA099996/CA/NCI NIH HHS|
|0/STAT3 Transcription Factor; EC 184.108.40.206/Proto-Oncogene Proteins c-akt; EC 220.127.116.11/Protein Kinase C-alpha; EC 18.104.22.168/Protein Kinase C-delta; EC 22.214.171.124/Protein Kinase C-epsilon|
|Cell Cycle. 2011 Jan 15;10(2):268-77
Journal ID (nlm-ta): Cell Cycle
Journal ID (iso-abbrev): Cell Cycle
Journal ID (publisher-id): CIB
Publisher: Landes Bioscience
Copyright © 2011 Landes Bioscience
Print publication date: Day: 01 Month: 2 Year: 2011
Electronic publication date: Day: 01 Month: 2 Year: 2011
pmc-release publication date: Day: 01 Month: 2 Year: 2011
Volume: 10 Issue: 3
First Page: 379 Last Page: 379
PubMed Id: 21270526
Publisher Id: KnudsenCC10-3
Publisher Item Identifier: 14740
|A tale of three PKCs : Epsilon emerges as a driver of pre-neoplastic phenotypes|
|Karen E. Knudsen|
|Thomas Jefferson University and Kimmel Cancer Center; Philadelphia, PA USA
|*Correspondence to: Email: firstname.lastname@example.org
The concept that classical and novel PKCs exert divergent outcomes in cancer has been long appreciated (reviewed in ref. 1). The PKC family of serine-threonine kinases is comprised of ten related members, including “classical” (cPCKs α, β, and γ), “atypical” (aPKCs ι/λ and ζ), and “novel” (nPKC δ, ε, η, and µ) subclasses according to structural motifs, calcium requirement and mechanisms of activation. The individual PKCs regulate diverse and sometimes opposing cellular processes such as proliferation, apoptosis, migration/motility, differentiation and, most notably, are thought to play unique roles in cancer development and progression. The potential impact of PKCs on tumor development was realized almost three decades ago when PKCs were identified as intracellular receptors for tumor-inducing phorbol esters.2 These initial discoveries ignited a season of discovery for discerning the overall influence of PKCs in tumorigenesis and tumor progression (reviewed in ref. 3).
Elegant in vitro and in vivo studies revealed that PKC functions in cancer are distinct among the kinases and show tissue specificity. For example, while PKCα does not alter skin cancer development in animal models, this isoform was identified as a critical mediator of proliferation in squamous cell carcinomas of the head and neck and as a marker of poor clinical outcome in this disease.4,5 Similarly conflicting data has been observed with PKCδ; this isoform has been shown to be anti-proliferative in animal models of skin cancer and exerts anti-tumor properties in rodent colon epithelia, but evidence supports a pro-survival role for PKCδ in cells derived from lung or breast cancer (reviewed in ref. 6). The divergent and context-specific functions of PKCs in cancer illuminate the urgent need to consider the tumor-specific and clinically relevant effects of PKC alterations using in vivo models.
In a recent study by Benavides, Kazanietz and colleagues,7 the impact of three distinct PKC isoforms was assessed using novel, prostate-specific transgenic models. Transgene expression was confined to the epithelial compartment, and animals homozygous for transgenic PKCα, PKCδ or PKCε expression were analyzed for histological changes after 12 mo. Notably, significant epithelial hyperplasia was observed in PKCε but not PKCα or PKCδ models, and similar results were observed in vitro upon individual expression of the three isoforms into human prostatic epithelial cells immortalized with viral oncoproteins. Combined, these findings reveal specificity of PKCε for inducing pro-proliferative effects in prostatic epithelia.
While no evidence of neoplastic lesion formation was observed in the PKCε animals, dysplastic changes characteristic of mPIN (murine prostatic intraepithelial neoplasia) developed in multiple lobes of the prostate. Subsequent investigation revealed that mPIN lesions in the PKCε-expressing compartments displayed concomitant hyperactivation of AKT. It will be of significant interest to determine if this event is requisite for PKCε-mediated phenotypes, as prostate-specific expression of AKT also drives formation of mPIN lesions that do not progress to neoplasia, and excessive AKT activation is thought to play a major role in human disease.8 In addition, a subset of PKCε overexpressing mPIN lesions exhibited elevation in total and activated Stat3. Given the putative oncogenic functions of Stat3 in human disease and the impact of Stat3 activation on tumor phenotypes,9 it is enticing to speculate that PKCε-positive tumors may show altered clinical behavior. Accordingly, the present study showed that PKCε expression conferred moderate resistance to castration. A caveat of the prostate-specific expression model is that the transgene is under control of an androgen-
dependent promoter (and is therefore attenuated in response to castration); nonetheless, the PKCε-transgenic epithelia showed a reduced apoptotic index after castration as compared with the PKCα or PKCδ transgenics.
Taken together, this tale of three PKCs defines the epsilon isoform as a driver of pre-neoplastic changes in the prostate, and provides an important new model with which to assess mechanism (including the role of AKT and Stat3), discern specificity of function, identify cooperative oncogenic factors and determine impact on therapeutic intervention. In this age of wisdom, wherein inhibitors of PKCs are both in development and in clinical trial, the present findings provide the impetus for developing PKCε as a putative new target for human prostate cancer.
Previously published online: www.landesbioscience.com/journals/cc/article/14740
|1.||Reyland ME. Protein kinase C isoforms: Multi-functional regulators of cell life and deathFront BiosciYear: 20091423869910.2741/338519273207|
|2.||Castagna M,Takai Y,Kaibuchi K,Sano K,Kikkawa U,Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol estersJ Biol ChemYear: 19822577847517085651|
|3.||Griner EM,Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancerNat Rev CancerYear: 200772819410.1038/nrc211017384583|
|4.||Jansen AP,Dreckschmidt NE,Verwiebe EG,Wheeler DL,Oberley TD,Verma AK. Relation of the induction of epidermal ornithine decarboxylase and hyperplasia to the different skin tumor-promotion susceptibilities of protein kinase C alpha, -delta and -epsilon transgenic miceInt J CancerYear: 2001936354310.1002/ijc.139511477572|
|5.||Cohen EE,Rosner MR. MicroRNA-regulated feed forward loop networkCell CycleYear: 200982477810.4161/cc.8.16.927119657226|
|6.||Gorin MA,Pan Q. Protein kinase C epsilon: an oncogene and emerging tumor biomarkerMol CancerYear: 2009198910.1186/1476-4598-8-919228372|
|7.||Benavides F,Blando J,Perez CJ,Garg R,Conti CJ,DiGiovanni J,et al. Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesionsCell CycleYear: 20111026827710.4161/cc.10.2.1446921224724|
|8.||Majumder PK,Grisanzio C,O'Connell F,Barry M,Brito JM,Xu Q,et al. A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer ProgressionCancer CellYear: 2008141465510.1016/j.ccr.2008.06.00218691549|
|9.||Yu H,Pardoll D,Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3Nat Rev CancerYear: 2009979880910.1038/nrc273419851315|
Previous Document: PKC? paves the way for prostate cancer.
Next Document: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer.